Literature DB >> 30439458

Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies.

Yu Chen1, Amy K Y Fu2, Nancy Y Ip3.   

Abstract

Alzheimer's disease (AD), the most prevalent neurodegenerative disease in the elderly population, is characterized by progressive cognitive decline and pathological hallmarks of amyloid plaques and neurofibrillary tangles. However, its pathophysiological mechanisms are poorly understood, and diagnostic tools and interventions are limited. Here, we review recent research on the amyloid hypothesis and beta-amyloid-induced dysfunction of neuronal synapses through distinct cell surface receptors. We also review how tau protein leads to synaptotoxicity through pathological modification, localization, and propagation. Finally, we discuss experimental therapeutics for AD and propose potential applications of disease-modifying strategies targeting synaptic failure for improved treatment of AD.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Beta-amyloid; Excitotoxicity; Kinase; Receptor; Synaptic failure; Tau

Mesh:

Substances:

Year:  2018        PMID: 30439458     DOI: 10.1016/j.pharmthera.2018.11.006

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  41 in total

1.  CaMKIIα Signaling Is Required for the Neuroprotective Effects of Dl-3-n-Butylphthalide in Alzheimer's Disease.

Authors:  Bing-Qiu Li; Ling-Zhi Xu; Fang-Yu Li; Ying Li; Yu Zhao; Heng Zhang; Mei-Na Quan; Jian-Ping Jia
Journal:  Mol Neurobiol       Date:  2022-03-19       Impact factor: 5.590

Review 2.  Deregulated mitochondrial microRNAs in Alzheimer's disease: Focus on synapse and mitochondria.

Authors:  Prashanth Gowda; P Hemachandra Reddy; Subodh Kumar
Journal:  Ageing Res Rev       Date:  2021-11-20       Impact factor: 10.895

3.  Integrated Bioinformatics Analysis to Identify Alternative Therapeutic Targets for Alzheimer's Disease: Insights from a Synaptic Machinery Perspective.

Authors:  Hamid Ceylan
Journal:  J Mol Neurosci       Date:  2021-08-19       Impact factor: 3.444

4.  Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment.

Authors:  Yuanyuan Lu
Journal:  Aging Clin Exp Res       Date:  2022-08-21       Impact factor: 4.481

Review 5.  Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing.

Authors:  Jiansong Fang; Andrew A Pieper; Ruth Nussinov; Garam Lee; Lynn Bekris; James B Leverenz; Jeffrey Cummings; Feixiong Cheng
Journal:  Med Res Rev       Date:  2020-07-13       Impact factor: 12.944

Review 6.  Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild Cognitive Impairment: A Narrative Review.

Authors:  Barry S Baumel; P Murali Doraiswamy; Marwan Sabbagh; Richard Wurtman
Journal:  Neurol Ther       Date:  2020-12-26

7.  A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.

Authors:  Niels D Prins; John E Harrison; Hui-May Chu; Kelly Blackburn; John J Alam; Philip Scheltens
Journal:  Alzheimers Res Ther       Date:  2021-05-27       Impact factor: 6.982

Review 8.  Structural Studies Providing Insights into Production and Conformational Behavior of Amyloid-β Peptide Associated with Alzheimer's Disease Development.

Authors:  Anatoly S Urban; Konstantin V Pavlov; Anna V Kamynina; Ivan S Okhrimenko; Alexander S Arseniev; Eduard V Bocharov
Journal:  Molecules       Date:  2021-05-13       Impact factor: 4.411

9.  Chemical Stimulation of Rodent and Human Cortical Synaptosomes: Implications in Neurodegeneration.

Authors:  Faraz Ahmad; Yu Jing; Albert Lladó; Ping Liu
Journal:  Cells       Date:  2021-05-12       Impact factor: 6.600

Review 10.  CD47 in the Brain and Neurodegeneration: An Update on the Role in Neuroinflammatory Pathways.

Authors:  Seyed Mohammad Gheibihayat; Ricardo Cabezas; Nikita G Nikiforov; Tannaz Jamialahmadi; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Molecules       Date:  2021-06-28       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.